文献速递艾滋病与性传播感染病毒性肝炎细菌感染、耐药与抗菌药物

2016-2019年美国11州接受阿片类使用障碍药物治疗的医疗补助参保者中人类免疫缺陷病毒、乙型肝炎病毒和丙型肝炎病毒检测的普及率

Prevalence of Testing for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among Medicaid Enrollees Treated With Medications for Opioid Use Disorder in 11 States, 2016-2019.
PubMed 文献 · Clin Infect Dis · 2023-01-01

该研究为系列横断面研究,纳入美国11州361537名医疗补助参保者共505440次阿片类使用障碍药物(MOUD)起始治疗,评估起始后90天内HIV、HBV、HCV检测率及趋势。2016至2019年,HIV检测率从20%升至25%,HBV从22%升至25%,HCV从24%升至27%,三项联合检测从15%升至19%,但多数参保者未接受检测。

要点

  • 2016至2019年,MOUD起始者中HIV、HBV、HCV及三项联合检测率均上升,但多数未检测。
  • 男性(对照非妊娠女性)、农村地区居民、起始美沙酮或纳曲酮者(对照丁丙诺啡)三项联合检测调整率更低。
  • 参保者特征与检测的关联在各州间存在差异。

核心结论

  • 在11个美国州的医疗补助参保者中,起始阿片类使用障碍药物治疗后,HIV、HBV、HCV及三项联合检测率在2016至2019年间上升,但多数人未接受检测。

研究设计与样本

  • 系列横断面研究,纳入2016至2019年美国11州361537名医疗补助参保者的505440次MOUD起始治疗。
  • 基于参保与索赔数据定义MOUD起始、HIV/HBV/HCV检测、合并症和人口学特征。
  • 各州采用泊松回归估计参保者特征与MOUD起始后90天内检测普及率的关联,并采用随机效应Meta分析汇总州级估计生成全局估计。

主要发现

  • 2016至2019年,HIV检测率从20%上升至25%,HBV从22%上升至25%,HCV从24%上升至27%,三项联合检测从15%上升至19%。
  • 三项联合检测的调整率在男性(对照非妊娠女性)、农村地区居民(对照城市地区)以及起始美沙酮或纳曲酮者(对照丁丙诺啡)中更低。
  • 参保者特征与检测的关联在各州间存在差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited information exists about testing for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) among Medicaid enrollees after starting medication for opioid use disorder (MOUD), despite guidelines recommending such testing. Our objectives were to estimate testing prevalence and trends for HIV, HBV, and HCV among Medicaid enrollees initiating MOUD and examine enrollee characteristics associated with testing. METHODS: We conducted a serial cross-sectional study of 505 440 initiations of MOUD from 2016 to 2019 among 361 537 Medicaid enrollees in 11 states. Measures of MOUD initiation; HIV, HBV, and HCV testing; comorbidities; and demographics were based on enrollment and claims data. Each state used Poisson regression to estimate associations between enrollee characteristics and testing prevalence within 90 days of MOUD initiation. We pooled state-level estimates to generate global estimates using random effects meta-analyses. RESULTS: From 2016 to 2019, testing increased from 20% to 25% for HIV, from 22% to 25% for HBV, from 24% to 27% for HCV, and from 15% to 19% for all 3 conditions. Adjusted rates of testing for all 3 conditions were lower among enrollees who were male (vs nonpregnant females), living in a rural area (vs urban area), and initiating methadone or naltrexone (vs buprenorphine). Associations between enrollee characteristics and testing varied across states. CONCLUSIONS: Among Medicaid enrollees in 11 US states who initiated medications for opioid use disorder, testing for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and all 3 conditions increased between 2016 and 2019 but the majority were not tested.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ahrens K, Sharbaugh M, Jarlenski MP, et al. Prevalence of Testing for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among Medicaid Enrollees Treated With Medications for Opioid Use Disorder in 11 States, 2016-2019. Clin Infect Dis. 2023. PMID: 36594172. doi:10.1093/cid/ciac981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。